시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 단순포진바이러스 치료 시장 보고서(2025년)
Herpes Simplex Virus Treatment Global Market Report 2025
상품코드 : 1824282
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,546,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,462,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,378,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 단순포진바이러스 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년까지 CAGR 7.5%로 확대되어 34억 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 항바이러스 요법의 진보, 예방 대책의 중시, 백신 개발의 가능성, 원격 의료 및 원격 진찰, 세계 헬스에 대한 대처 등에 기인하고 있습니다. 예측기간의 주요 동향으로는 나노기술의 도입, 원격상담을 위한 원격의료, 자연요법과 허브요법, 신생아 포진 예방전략, 항바이러스제 내성 모니터링 등이 있습니다.

향후 5년간의 성장률 7.5%라는 예측은 지난 예측으로부터 0.2% 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 장벽은 인도와 이스라엘에서 조달하는 아시클로비르와 발라시클로비르의 비용을 증가시켜 미국을 방해하고 바이러스 발생을 늘리고 감염성 관리 비용을 증가시킬 것으로 예측됩니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 보다 광범위하게 이어질 수 있습니다.

성감염증(STI) 증가율은 단순포진바이러스(HSV) 치료 시장의 향후 확대를 견인할 것으로 예측됩니다. STI(성감염)는 특정 세균, 바이러스 및 기타 미생물의 감염으로 인한 질병으로, 감염자와의 성행위 중에 혈액, 정액, 질액 및 기타 체액을 통해 감염됩니다. HSV 치료는 주로 요도염, 자궁 경관염, 성기 궤양으로 이어지는 감염과 같은 성감염을 다루는 것입니다. 예를 들어, 2024년 3월 영국 의회는 STI의 현저한 증가를 보고하고 임질 진단이 41.3% 증가했으며 2021년 2만 7,545명에서 2022년 3만 8,923명으로 급증했다고 강조했습니다. 유사하게, 클라미디아 증례는 25.3% 증가하였고, 15,267례에서 19,129례로 증가하였고, 동시기에 감염성 매독 증례는 12.9% 증가하였으며, 5,316례에서 6,003례로 증가하였습니다. 따라서 STI 유병률 증가는 단순포진바이러스 치료 시장 성장에 박차를 가하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

JHS
영문 목차

영문목차

Herpes simplex virus treatment involves addressing infections caused by the herpes simplex virus (HSV), commonly known as herpes, which can result in painful blisters or ulcers. This treatment aims to manage the symptoms of the viral infection through the use of antiviral creams or tablets.

The main types of herpes simplex virus treatment are for herpes simplex virus-1 infection and herpes simplex virus-2 infection. Herpes simplex virus type 1 (HSV-1) belongs to the Alphaherpesviridae subfamily, characterized by a linear double-stranded DNA virus. The various drugs used for treatment include acyclovir, valacyclovir, famciclovir, and others. Treatment can be administered through oral, injection, or topical routes. Several types of vaccines, including Simplirix and others, are available and sold through various distribution channels such as hospital pharmacies, drug stores, retail pharmacies, and online providers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The herpes simplex virus treatment market research report is one of a series of new reports from The Business Research Company that provides herpes simplex virus treatment market statistics, including herpes simplex virus treatment industry global market size, regional shares, competitors with a herpes simplex virus treatment market share, detailed herpes simplex virus treatment market segments, market trends and opportunities, and any further data you may need to thrive in the herpes simplex virus treatment industry. This herpes simplex virus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The herpes simplex virus treatment market size has grown strongly in recent years. It will grow from $2.41 billion in 2024 to $2.55 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to the increased prevalence of HSV infections, antiviral medications development, clinical research and drug approvals, patient education and awareness, and global efforts for std prevention.

The herpes simplex virus treatment market size is expected to see strong growth in the next few years. It will grow to $3.4 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to advancements in antiviral therapies, focus on preventive measures, potential vaccine development, telemedicine and remote consultations, global health initiatives. Major trends in the forecast period include incorporation of nanotechnology, telemedicine for remote consultations, natural and herbal therapies, strategies for neonatal herpes prevention, antiviral drug resistance monitoring.

The forecast of 7.5% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of acyclovir and valacyclovir sourced from India and Israel, thereby prolonging viral outbreaks and elevating infectious disease management costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising rates of sexually transmitted infections (STIs) are anticipated to drive the expansion of the herpes simplex virus (HSV) treatment market in the future. STIs, or sexually transmitted diseases (STDs), are illnesses caused by infections with specific bacteria, viruses, or other microorganisms that can be transmitted through blood, semen, vaginal fluids, or other body fluids during sexual activity with an infected individual. HSV treatment primarily addresses sexually transmitted conditions such as urethritis, cervicitis, and infections leading to genital ulcers. For example, in March 2024, the UK Parliament reported a notable increase in STIs, highlighting a 41.3% rise in gonorrhea diagnoses, which jumped from 27,545 in 2021 to 38,923 in 2022. Similarly, chlamydia cases saw a 25.3% increase, rising from 15,267 to 19,129, while infectious syphilis cases grew by 12.9%, from 5,316 to 6,003 during the same timeframe. Thus, the increase in STI prevalence is fueling the growth of the HSV treatment market.

Urbanization is expected to be a driving force behind the growth of the herpes simplex virus treatment market. Urbanization, a process fueled by economic development and industrialization, transforms rural areas into urban centers. The prevalence of HSV treatment in urban populations is attributed to higher population density, improved healthcare accessibility, and increased awareness, making it a more viable option for controlling the virus's spread in urban settings. According to the World Bank Group's April 2023 estimates, over half of the global population resides in urban areas, and this urban population is projected to grow to 6 billion, marking a 1.5 times increase by 2045. Therefore, urbanization is a significant factor driving the herpes simplex virus treatment market.

A notable trend gaining traction in the herpes simplex virus treatment market is the innovation of HSV treatments. Major companies in the market are actively engaged in developing new treatments and drugs to maintain their market position. For instance, in October 2022, Replay Therapeutics, a US-based genome writing company, introduced Eudora, its first HSV gene therapy company focusing on retinal eye disease. Eudora is the first product using synHSVTM, a high-payload-capacity HSV delivery vector, within Replay's distinct corporate structure that separates the development of technological and medicinal products. This innovative approach aims to address monogenic brain, skin, and muscle illnesses using big DNA gene therapy.

Leading companies in the herpes simplex virus treatment market are directing their efforts toward developing advanced tests, such as chip-based RT-PCR tests, to meet the demand for efficient diagnostic solutions and enhance market profitability. The chip-based RT-PCR test utilizes microchip technology for rapid and efficient nucleic acid amplification through reverse transcription-polymerase chain reaction. In January 2023, Molbio Diagnostics, an India-based molecular diagnostics manufacturer, launched Truenat HSV 1/2, a chip-based RT-PCR test approved by CDSCO for swift herpes diagnosis. This test, compatible with the Truelab infrastructure, provides sample-to-results in an hour without additional setup, employing real-time PCR technology to distinguish between HSV-1 and HSV-2, aiding in the prompt detection of oral and genital herpes.

In April 2023, SK Capital acquired Apotex Pharmaceutical Holdings Inc for an undisclosed amount, aiming to leverage Apotex's iconic brand, extensive product portfolio, international presence, and skilled team to establish itself as a leading global player in the pharmaceutical industry. Apotex Pharmaceutical Holdings, based in Canada, is a pharmaceutical company providing tablets for herpes virus treatment.

Major companies operating in the herpes simplex virus treatment market include GlaxoSmithKline plc, Carlsbad Technology Inc., Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Apotex Inc., Mylan N.V., Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Novartis AG, Zydus Pharmaceuticals Inc., Abbott Laboratories, Amneal Pharmaceuticals Inc., Pfizer Inc., Viatris Inc., Agenus Inc., Merck KGaA, Chimerix Inc., Avet Pharmaceuticals Inc., EPI Health LLC, Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Gilead Sciences Inc., Bayer AG, Eli Lilly and Company, BioCryst Pharmaceuticals Inc., AiCuris Anti-infective Cures GmbH, CureVac AG

North America was the largest region in the herpes simplex virus treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global herpes simplex virus treatment market report during the forecast period. The regions covered in the herpes simplex virus treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the herpes simplex virus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The herpes simplex virus treatment market consists of sales of docosanol and penciclovir. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Herpes Simplex Virus Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on herpes simplex virus treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for herpes simplex virus treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The herpes simplex virus treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Herpes Simplex Virus Treatment Market Characteristics

3. Herpes Simplex Virus Treatment Market Trends And Strategies

4. Herpes Simplex Virus Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Herpes Simplex Virus Treatment Growth Analysis And Strategic Analysis Framework

6. Herpes Simplex Virus Treatment Market Segmentation

7. Herpes Simplex Virus Treatment Market Regional And Country Analysis

8. Asia-Pacific Herpes Simplex Virus Treatment Market

9. China Herpes Simplex Virus Treatment Market

10. India Herpes Simplex Virus Treatment Market

11. Japan Herpes Simplex Virus Treatment Market

12. Australia Herpes Simplex Virus Treatment Market

13. Indonesia Herpes Simplex Virus Treatment Market

14. South Korea Herpes Simplex Virus Treatment Market

15. Western Europe Herpes Simplex Virus Treatment Market

16. UK Herpes Simplex Virus Treatment Market

17. Germany Herpes Simplex Virus Treatment Market

18. France Herpes Simplex Virus Treatment Market

19. Italy Herpes Simplex Virus Treatment Market

20. Spain Herpes Simplex Virus Treatment Market

21. Eastern Europe Herpes Simplex Virus Treatment Market

22. Russia Herpes Simplex Virus Treatment Market

23. North America Herpes Simplex Virus Treatment Market

24. USA Herpes Simplex Virus Treatment Market

25. Canada Herpes Simplex Virus Treatment Market

26. South America Herpes Simplex Virus Treatment Market

27. Brazil Herpes Simplex Virus Treatment Market

28. Middle East Herpes Simplex Virus Treatment Market

29. Africa Herpes Simplex Virus Treatment Market

30. Herpes Simplex Virus Treatment Market Competitive Landscape And Company Profiles

31. Herpes Simplex Virus Treatment Market Other Major And Innovative Companies

32. Global Herpes Simplex Virus Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Herpes Simplex Virus Treatment Market

34. Recent Developments In The Herpes Simplex Virus Treatment Market

35. Herpes Simplex Virus Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기